Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Aug 14, 2025
Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy
Read more at globenewswire.com
